| HYPMY Stock | | | USD 3.35 0.11 3.18% |
Director
Mr. Breno Toledo Pires de Oliveira serves as the Investor Relations Officer and a Member of the Executive Board of Hypermarcas SA since September 27, 2011. Within the Company, he is a Member of the Ethics Committee. He began his career at Banco Bozano, Simonsen, in 1997, and since then has performed several roles in the financial area, including resource management and investment analysis. He joined the group in 2004 and began working at the Company in 2008 as Director of Financial Planning. Since then, he has participated in the areas of mergers and acquisitions, treasury and finance. He graduated in Business Administration from Fundacao Getulio Vargas and gained a Masters of Business Administration from the University of Chicago. since 2017.
| Age | 40 |
| Tenure | 7 years |
| Phone | 55 11 3627 4206 |
| Web | https://www.hyperapharma.com.br |
Hypera SA Management Efficiency
The company has return on total asset
(ROA) of
0.0686 % which means that it generated a profit of $0.0686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1626 %, meaning that it generated $0.1626 on every $100 dollars invested by stockholders. Hypera SA's management efficiency ratios could be used to measure how well Hypera SA manages its routine affairs as well as how well it operates its assets and liabilities.
Hypera SA has accumulated 6.8
B in total debt with debt to equity ratio
(D/E) of 0.8, which is about average as compared to similar companies. Hypera SA has a current ratio of 1.73, which is within standard range for the sector. Debt can assist Hypera SA until it has trouble settling it off, either with new capital or with free cash flow. So, Hypera SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hypera SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hypera to invest in growth at high rates of return. When we think about Hypera SA's use of debt, we should always consider it together with cash and equity.
It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypermarcas ADR operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 9000 people. Hypera SA [HYPMY] is a
Pink Sheet which is traded through a dealer network over-the-counter (OTC).
Management Performance
Hypera SA Leadership Team
Elected by the shareholders, the Hypera SA's board of directors comprises two types of representatives: Hypera SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hypera. The board's role is to monitor Hypera SA's management team and ensure that shareholders' interests are well served. Hypera SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hypera SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Adalmario Couto, Investor CFO | |
| Juliana Salem, Legal Officer | |
| Hlio Segouras, Head Health | |
| Joao Aguilar, Risks Officer | |
| Mauricio Christovam, HR Officer | |
| Breno Oliveira, Chief Investor Relations Officer and Treasury Director | |
| Nelson Mello, Institutional Relations Officer, Member of the Executive Board | |
| Carlos Scorsi, Chief Operating officer | |
| Luiz Clavis, VP Marketing | |
| Martim Mattos, CFO and Secretary | |
Hypera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hypera SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Hypera Pink Sheet Analysis
When running Hypera SA's price analysis, check to
measure Hypera SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hypera SA is operating at the current time. Most of Hypera SA's value examination focuses on studying past and present price action to
predict the probability of Hypera SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hypera SA's price. Additionally, you may evaluate how the addition of Hypera SA to your portfolios can decrease your overall portfolio volatility.